Company intelligence / Profile preview

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Shanghai, Shanghai, Chinafd-zj.com ↗

Ownership: Private
Employees: ~948
Development stage: Commercial

Overview

The company has approved products in China including Hemoporfin and is conducting multiple clinical trials across different phases for its pipeline products. Recently announced a price reduction for Doxorubicin hydrochloride liposome injection.

Therapeutic areas: GastroenterologyImmunologyDermatologyOncologyNeurologyInfectious Diseases
Modalities: Antibody drug conjugates (ADC)Small molecule drugsMonoclonal antibodiesFusion proteinsLiposomal drugsPhotodynamic technology drugs
Industry: Biotech

Drug pipeline

13 assets

hemoporfin

12 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd..

Explore the full profile